 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the...

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus...

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull Case...

Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull Case

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Companys Board of Directors. Dr. Aggarwal has been...

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Bank of Montreal Can purchased a new position in Geron Co. (NASDAQ:GERN  Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and...

34,570 Shares in Geron Co. (NASDAQ:GERN) Bought by Bank of Montreal Can

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Geron participates in a conference call with Truist

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 438,950 shares of Geron...

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors considering a purchase of Geron Corp. (GERN) stock, but tentative about paying the going market price of 1.85/share, might benefit from considering selling puts among the alternative...

Commit To Purchase Geron At $1.50, Earn 16.7% Using Options

Shares of Geron Co. (NASDAQ:GERN  Get Free Report) reached a new 52-week low during trading on Thursday . The stock traded as low as $1.72 and last traded at $1.74, with a volume of 1807783...

Geron (NASDAQ:GERN) Hits New 12-Month Low at $1.72

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Watchers	20,317
52-Wk Low	$1.68
52-Wk High	$3.84

Market Cap	$1.01B
Volume (M)	6.17M
52-Wk High	$3.84
52-Wk Low	$1.68

GERN Geron Corp.

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community